287 million people were living with chronic hepatitis B or C in 2024. Fewer than 5% of the 240 million with hepatitis B were receiving treatment, and only 20% of people with hepatitis C have been treated since 2015.
Pantoprazole, rabeprazole and esomeprazole are each held in standalone and fixed-combination form, across 101 oral presentations.
Range depth
21 pantoprazole, 22 esomeprazole, 14 rabeprazole presentations.
Ursodeoxycholic acid and hepatic encephalopathy lines.
Delayed-release presentations to USP.
36 injectable lines in the category.
We establish what is already registered in your market, who supplies it today, and where demand is going unmet.
We set your current range against the portfolio and separate genuine gaps from lines you already stock.
You get the molecules in filing order, which of them need a dossier built for your authority, and which fall outside the range.
We compile the dossier in CTD format for your authority and supply the COPP and plant-level WHO-GMP and PIC/S certificates behind it.
We analyse your market and set your existing range against the portfolio, then return the molecules worth filing in priority order with the documentation route for each.